| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2006;37:2744.)
© 2006 American Heart Association, Inc.
Original Contributions |
From the Stroke & Neural Stem Cell Laboratory in the Clinical Research Inst, Stem Cell Research Center, Department of Neurology, Seoul National University Hospital, Seoul, South Korea.
Correspondence to Jae-Kyu Roh, MD, PhD, Department of Neurology, Seoul National University Hospital, 28, Yongon-dong, Chongro-gu, Seoul, 110-744, South Korea. E-mail rohjk{at}snu.ac.kr
| Abstract |
|---|
|
|
|---|
Methods Cerebral ischemia-reperfusion injury was induced by intraluminal thread occlusion of middle cerebral artery in the adult male rats. Solutions of sodium nitrite were infused intravenously at the time of reperfusion. Sodium nitrate and carboxy-PTIO (30 minutes before ischemic surgery), a direct NO scavenger, were infused for comparisons.
Results Nitrite reduced infarction volume and enhanced local cerebral blood flow and functional recovery. The effects were observed at concentrations of 48 nmol and 480 nmol, but not at 4800 nmol nitrite and 480 nmol nitrate. The neuroprotective effects of nitrite were inhibited completely by the carboxy-PTIO. The 480 nmol nitrite attenuated dihydroethidium activity, 3-nitrotyrosine formation, and lipid peroxidation in the ischemic brain.
Conclusions Nitrite exerted profound neuroprotective effects with antioxidant properties in the ischemic brains. These results suggest that nitrite, as a biological storage reserve of NO, may be a novel therapeutic agent in the setting of acute stroke.
Key Words: cerebral ischemia-reperfusion injury neuroprotection nitric oxide nitrite oxidative stress
| Introduction |
|---|
|
|
|---|
NO synthase (NOS) is a dominant physiological source of NO. However, the enzymatic activity of NOS requires oxygen and is blocked under hypoxia. Therefore, alternative pathways for hypoxic release of NO have high physiological relevance. The agents that liberate NO have been recognized as highly critical for therapeutic purposes especially in ischemic disorders. A variety of structurally different NO donors have been shown to limit infarct size by improving blood flow in the penumbra areas and reducing the oxidative stress in an NO-dependent fashion.911 Recent works support the application of nitrite as a direct NO donor for treatment of ischemic disorders. The anion nitrite is reduced to form NO as a result of reduction by deoxyhemoglobin, myoglobin, tissue heme proteins, and nonenzymatic disproportionating.12,13 The NO release from nitrite, and in parallel the vasodilatory effect, are increased under conditions of acidosis, hypoxia, and tissue I/R.14 This improved understanding of the biochemical conversion of nitrite to NO has resulted in a great deal of interest in the potential beneficial effects of nitrite therapy in animal models of ischemia.13
The ischemic cerebral environment might allow for the acidic and hypoxic reduction of nitrite to NO. In this study, we investigated whether hypoxia-dependent NO production from nitrite in ischemic brain might limit I/R injury.
| Materials and Methods |
|---|
|
|
|---|
Experimental Protocols
The drug-treated rats were randomly assigned to nitrite-treated, nitrate-treated, and carboxy-PTIO-nitrite groups. Sodium nitrite and sodium nitrate (Sigma-Aldrich) were dissolved in phosphate-buffered saline and the pH was adjusted to 7.4. In all experiments, a final volume of 500 µL containing sodium nitrite (48 to 4800 nanomoles) or sodium nitrate (480 nmol) was administered intravenously to the rats for 1 minute via intravenous cannula situated in the tail vein at the time of reperfusion. Carboxy-PTIO [2-(4-carboxyphenyl)-4, 4, 5, 5-tetramethylimidazoline-1-oxyl-3-oxide potassium salt], a direct intravascular NO scavenger, was used to inhibit NO-dependent effects. Carboxy-PTIO (Alexis Biochemicals) was dissolved in phosphate-buffered saline and was administered intravenously at a dose of 1 mg/kg in a volume of 500 µL, 30 minutes before ischemia.
Evaluation of Infarct Volume
We measured infarction volumes (at 1 day after I/R, n=12 per group) using 2,3,5-triphenyltetrazolium chloride (TTC; Sigma) staining, as described elsewhere.15 The infarcted and total hemispheric areas of each section, at intervals of 1-mm thickness, were traced and measured using an image analysis system (Image-Pro Plus; Media Cybernetics). Two investigators blinded to the study protocol measured the infarct sizes with a computerized image analyzer. To compensate for the effect of brain edema, the corrected infarct volume was calculated: Corrected infarct area=Measured infarct areax{1[(Ipsilateral hemisphere areaContralateral hemisphere area)/Contralateral hemisphere]}.15
Local Cerebral Blood Flow Measurement
Laser-Doppler flowmetry (Perimed; Probe 403, Sweden) was performed to monitor local cerebral blood flow (LCBF) of ischemic cortical area supplied by the MCA throughout the I/R process. The animals were placed with the head immobilized in a stereotaxic frame and the probe was placed in a burr hole over the parietal cortex distal to the site of core ischemic damage. The LCBF was determined before ischemia, during ischemia, and then for 3 hours after injection of drug at the reperfusion. Flow values shown were expressed as percent of baseline.
Neurological Scores
To examine the effects of the nitrite (480 nmol) on the neurological deficits of rats after cerebral I/R, behavioral tests were performed by 2 investigators blinded to the treatment status of the rats with modified limb placing tests (MLPT) and Rotorod test.15,16 The animals were monitored during the period of postoperative recovery starting at 2 hours, or 1, 3, or 7 days after I/R (n=6 per group).
Cyclic Guanosine Monophosphate Measurement in Brain Tissue
Levels of cyclic guanosine monophosphate (cGMP) in the ipsilateral hemisphere of ischemic brain with saline, nitrite (480 nmol), or nitrite (480 nmol) treatment after stroke in rats were measured (n=3 per group). The animals were killed at 1 day after I/R and the ipsilateral hemisphere cortical tissue was rapidly dissected. Levels of cGMP were measured using a commercially available low pH Immunoassay kit (R&D Systems Inc) according to the manufacturers instruction. Values for cGMP were standardized by total protein (picomolars per milligrams tissue).
Analysis of Superoxide and Peroxynitrite Formation
Three hours after reperfusion, the rat brains were processed for the analysis of oxidative and nitrative stress (n=6 per group). The oxidative fluorescent dye dihydroethidium (DHE; Sigma-Aldrich) was used to evaluate in situ production of superoxide.17 Frozen enzymatically intact brains were cut into 30-µm-thick sections and placed on a glass slide. The sections were simultaneously incubated with DHE (10 µmol/L) in phosphate-buffered saline for 30 minutes at 37°C, in a humidified chamber that was shielded from light. We also monitored peroxynitrite formation by detecting nitrosylated tyrosine residues on proteins. We performed immunostaining with anti-3-nitrotyrosine (3-NT) antibody (1:1000; Upstate Biotechnology). Coronal sections cut through the striatum (3 sections per brain, 1 mm in width) were imaged in parallel. Superoxide or 3-NTpositive cells were manually counted in the eight regions around the striatum under x100 magnification using a laser scanning confocal microscopy with a Bio-Rad MRC 1024 (argon and krypton).
Measurement of Lipid Peroxidation
Malondialdehyde (MDA) was estimated as an indicator of lipid peroxidation (n=3 per group). The brain tissues were homogenized with sodium phosphate buffer (pH 7.4). The reagents (1.5 mL acetic acid, 1.5 mL thiobarbituric acid, and 0.2 mL sodium dodecyl sulfate) were added to 0.1 mL of processed tissue sample. The mixture was then heated at 100°C for 60 minutes. The mixture was cooled with tap water and 5 mL of n-butanol: pyridine (15:1) and 1 mL of distilled water was added. After centrifugation at 4000 rpm for 10 minutes, the organic layer was withdrawn and absorbance was measured at 532 nm using a spectrophotometer.
Statistical Analysis
All data in this study are expressed as means±standard deviations. Data were analyzed by 1-way analysis of variance (ANOVA) followed by Tukey test (when appropriate) or Student t test if they were normally distributed. In the case of LCBF measurement, values of different time points were compared by 2-way repeated measures ANOVA. Without normal distribution, we used the MannWhitney U test. P<0.05 was regarded as statistically significant.
| Results |
|---|
|
|
|---|
|
Nitrite Treatment Enhanced Local Cerebral Blood Flow Without Blood Pressure Changes
The experimental groups did not differ with respect to the pre-ischemic, intra-ischemic, or postischemic rectal temperature, arterial blood gases, and pH values. Mean arterial blood pressure also showed no significant differences between saline-treated and nitrite-treated (480 nmol) animals until 60 minutes after drug administration (see Table I, available at http://stroke.ahajournals.org). Dynamic changes in ipsilateral LCBF measured by laser-Doppler flowmetry were measured starting 30 minutes before induction of ischemia until 3 hours after reperfusion. In all groups, MCA occlusion resulted in an immediate reduction of LCBF to
10% of baseline. After reperfusion, a short period of postischemic hyperemia was followed by a decrease below normal values. The LCBF significantly increased in the ischemic hemisphere in intermediate-dose nitrite treatment (480 nmol; range, 158±12% to 102±10%), but not in nitrate treatment (480 nmol; range, 140±18% to 63±9%), immediately after drug administration at the reperfusion (Figure 2A; n=3, P<0.05, ANOVA). The increase in LCBF was independent of changes in arterial pressure and blood gases.
|
|
Nitrite Treatment Promoted Functional Recovery
The reduction in infarct volume by nitrite (480 nmol) was associated with a better performance on the MLPT and Rotorod test. Both the nitrite-treated group and the ischemia-control group exhibited equal deficits in neurological scale at 2 hours after I/R. The nitrite-treated group showed less neurological deficit and exhibited better recovery characteristics, with significant difference from day 1 after I/R (Figure 2B, 2C; n=6, P<0.01, t test). At day 7, the group of rats which had been treated with nitrite scored <2 points on the MLPT and exhibited a 25% better recovery on the rotarod test.
Neuroprotective Effects of Nitrite Are Dependent on NO
Although the carboxy-PTIO alone did not aggravate the infarct volume, pretreatment with carboxy-PTIO completely abolished the protective effects of nitrite therapy (Figure 3E; n=12, ANOVA and Tukeys test). In addition, we evaluated the effect of nitrite (480 nmol) or nitrate (480 nmol) on the levels of cGMP in ipsilateral cortex of rats with I/R injury. Saline-treated rats after I/R exhibited a significantly higher level of cortical cGMP compared with normal control rats. Administration of nitrite significantly increased cGMP (2.0±0.4 pmol/mg, P<0.05) compared with the saline-treated (1.4±0.3 pmol/mg) or nitrate-treated (1.4±0.3 pmol/mg) group in the ipsilateral hemisphere at 1 day after I/R (Figure 3F; n=3, P<0.05, ANOVA and Tukey test).
|
Adequate Dose of Nitrite Reduced the Oxidative Stress in the Ischemic Brain
In the normal rats, few evidence of DHE-induced EtBr fluorescence or 3-NT immunoreactivity was observed in the cortex and striatum. Superoxide-generating cells and 3-NTpositive cells were increased in the ischemic hemisphere (192±20, 103±23 cells per section, respectively), whereas only a few labeled cells were detected in the nonischemic hemisphere (Figure 4). Data from image analysis indicated decreases of superoxide (51±18 cells per section) and 3-NT production (44±19 cells per section) in the 480 nmol nitrite-treated group, compared with the ischemia-control group (Figure 4; n=6, P<0.05, ANOVA and Tukey test). In contrast, higher concentration of nitrite (4800 nmol) failed to attenuate the superoxide production (169±23 cells per section), and rather increased the 3-NT formation (138±12 cells per section) in the ischemic brain. These histological results were further supported by biochemical assay for MDA, a lipid peroxidation product. Nitrite (480 nmol) significantly decreased the levels of MDA (0.31±0.06 µg/mg protein) as compared with the saline-treated group (0.42±0.04 µg/mg protein) (Figure 4H; n=3, P<0.05, MannWhitney U test).
|
| Discussion |
|---|
|
|
|---|
The vascular mechanism is responsible for the neuroprotective effect of nitrite. Low and nontoxic doses of sodium nitrite were able to increase LCBF rapidly in the ischemic brain without concomitant hypotension. These results support the concept that the biological activity of NO can exist in the local circulation around the ischemic brain. To further clarify a mechanism involving the hypoxic reduction of nitrite to NO, we preceded nitrite with carboxy-PTIO. The carboxy-PTIO has been reported to react with NO to generate NO2 and PTI derivative in a stoichiometric manner.21 In this study, the carboxy-PTIO completely inhibited protective effects of nitrite in the ischemic brain, suggesting the NO-dependent action of nitrite. In addition, our data that carboxy-PTIO alone did not affect the infarct size suggested that the carboxy-PTIO might preferentially quench the biological action of excess NO without affecting NOS activity or endogenous nitrite. Because the formation of carboxy-PTI and/or NO2 may complicate the interpretation of data, the possibility that its reaction products contribute to the antagonism should be also considered.
The indirect way of demonstrating the NO-dependent mechanism of nitrite is to measure the degree to which NO receptors in the tissue are active. NO receptors possess intrinsic guanylyl cyclase activity, and so when they are stimulated, cGMP accumulates in the cells.22 Our data that nitrite treatment increased the cGMP level in the cerebral I/R supported that nitrite effect was mediated via a NO/guanylyl cyclase/cGMP pathway. However, S-nitrosothiols and N-nitrosamines formed via reactions of nitrite with deoxyhemoglobin and possibly tissue heme proteins may have critical effects on protection against I/R injury.23 To further demonstrate the pharmacological profiles of nitrite in the cerebral I/R paradigm, the new analyzing techniques need to be developed to discriminate between the various NO-related compounds.
Another important finding in this study is that the nitrite effect is dose-dependent. NO is highly reactive with other free radicals, and the reaction between NO and superoxide can promote protection by reducing superoxide toxicity.3,4 However, NO produced in massive outbursts may form a stronger oxidant peroxynitrite with resultant protein nitration, DNA damage, and energy failure.24 It is now well appreciated that very high, nonphysiological levels of NO actually promote cellular necrosis and apoptosis, whereas the demonstrated protective effects of NO typically involve nanomolar or low micromolar concentrations of NO.8 In our study, the 480 nmol nitrite could confer the antioxidant effects in the ischemic brain, whereas the detrimental effects of high dose of nitrite after I/R were most likely secondary to nitrite-mediated generation of superoxide or peroxynitrite. Therefore, the strategies simply increasing NO in ischemic cortex may even exacerbate the I/R injury.
Targeting neurovascular protection by structurally suitable NO donor in the ischemic brain might be effective candidates for the treatment of acute stroke. Our observations not only expand our understanding of the physiological roles of NO in the brain but also offer novel treatment strategies targeting the efficient NO donation.
| Acknowledgments |
|---|
This study was supported by a Korean Research Foundation grant funded by the Korean Government (MOEHRD, Basic Research Promotion Fund, KRF-2005-015-E00182).
Disclosures
None.
| Footnotes |
|---|
Received July 20, 2006; accepted August 10, 2006.
| References |
|---|
|
|
|---|
2. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci. 1997; 20: 132139.[Medline] [Order article via Infotrieve]
3. Stagliano NE, Dietrich WD, Prado R, Green EJ, Busto R. The role of nitric oxide in the pathophysiology of thromboembolic stroke in the rat. Brain Res. 1997; 759: 3240.[CrossRef][Medline] [Order article via Infotrieve]
4. Mohanakumar KP, Thomas B, Sharma SM, Muralikrishnan D, Chowdhury R, Chiueh CC. Nitric oxide: an antioxidant and neuroprotector. Ann N Y Acad Sci. 2002; 962: 389401.[Medline] [Order article via Infotrieve]
5. Beckman JS. Interactions of oxidants, nitric oxide, and antioxidant defenses in cerebral ischemia and injury. In: Ginsberg MD, Bogousslavsky J, eds. Cerebrovascular Disease. Boston, MA: Blackwell Science; 1998: 455470.
6. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001; 32: 980986.
7. Buisson A, Margaill I, Callebert J, Plotkine M, Boulu RG. Mechanisms involved in the neuroprotective activity of a nitric oxide synthase inhibitor during focal cerebral ischemia. J Neurochem. 1993; 61: 690696.[Medline] [Order article via Infotrieve]
8. Dimmeler S, Zeiher AM. Nitric oxide and apoptosis: another paradigm for the double-edged role of nitric oxide. Nitric Oxide. 1997; 1: 275281.[CrossRef][Medline] [Order article via Infotrieve]
9. Zhang R, Zhang L, Zhang Z, Wang Y, Lu M, Lapointe M, Chopp M. A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats. Ann Neurol. 2001; 50: 602611.[CrossRef][Medline] [Order article via Infotrieve]
10. Zhang F, White JG, Iadecola C. Nitric oxide donors increase blood flow and reduce brain damage in focal ischemia: evidence that nitric oxide is beneficial in the early stages of cerebral ischemia. J Cereb Blood Flow Metab. 1994; 14: 217226.[Medline] [Order article via Infotrieve]
11. Morikawa E, Moskowitz MA, Huang Z, Yoshida T, Irikura K, Dalkara T. L-arginine infusion promotes nitric oxide-dependent vasodilation, increases regional cerebral blood flow, and reduces infarction volume in the rat. Stroke. 1994; 25: 429435.[Abstract]
12. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schecter AN, Cannon RO, Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the circulation. Nat Med. 2003; 9: 14981505.[CrossRef][Medline] [Order article via Infotrieve]
13. Duranski MR, Greer JMG, Dejam A, Jaganmohan S, Hogg N, Langston W, Patel RP, Yet SF, Wang Xunde Kevil CG, Gladwin MT, Lefer DJ. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest. 2005; 115: 12321240.[CrossRef][Medline] [Order article via Infotrieve]
14. Modin A, Bjorne H, Herulf M, Alving K, Weitzberg E, Lundberg JO. Nitrite-derived nitric oxide: a possible mediator of acidic-metabolic vasodilation. Acta Physiol Scand. 2001; 171: 916.[CrossRef][Medline] [Order article via Infotrieve]
15. Lee ST, Chu K, Jung KH, Ko SY, Kim EH, Sinn DI, Lee YS, Lo EH, Kim M, Roh JK. Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia. Brain Res. 2005; 1058: 120128.[CrossRef][Medline] [Order article via Infotrieve]
16. Jung KH, Chu K, Jeong SW, Han SY, Lee ST, Kim JY, Kim M, Roh JK. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke. 2004; 35: 17441749.
17. Bindokas VP, Jordan J, Lee CC, Miller RJ. Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. J Neurosci. 1996; 16: 13241336.
18. Hunter CJ, Dejam A, Blood AB, Shields H, Kim-Shapiro DB, Machado RF, Tarekegn S, Mulla N, Hopper AO, Schechter AN, Power GG, Gladwin MT. Inhaled nebulized nitrite is a hypoxiasensitive NO-dependent selective pulmonary vasodilator. Nat Med. 2004; 10: 11221127.[CrossRef][Medline] [Order article via Infotrieve]
19. Pluta RM, Dejam A, Grimes G, Gladwin MT, and Oldfield EH. Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA. 2005; 293: 14771484.
20. Basireddy M, Isbell TS, Teng X, Patel RP, Agarwal A. Effects of sodium nitrite on ischemia-reperfusion injury in the rat kidney. Am J Physiol Renal Physiol. 2006; 290: F779F786.
21. Akaike T, Yoshida M, Miyamoto Y, Sato K, Kohno M, Sasamoto K, Miyazaki K, Ueda S, Maeda H. Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/NO through a radical reaction. Biochemistry. 1993; 32: 827832.[CrossRef][Medline] [Order article via Infotrieve]
22. Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol. 1995; 57: 683706.[CrossRef][Medline] [Order article via Infotrieve]
23. Mannick JB, Hausladen A, Liu L, Hess DT, Zeng M, Miao QX, Kane LS, Gow AJ, Stamler JS. Fas-induced caspase denitrosylation. Science. 1999; 284: 651654.
24. Schopfer F, Baker PRS, Freeman BA. NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response? Trends Biochem Sci. 2003; 28: 646654.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
J. W. Calvert and D. J. Lefer Myocardial protection by nitrite Cardiovasc Res, July 15, 2009; 83(2): 195 - 203. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. O. Lundberg Cardiovascular prevention by dietary nitrate and nitrite Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1221 - H1223. [Full Text] [PDF] |
||||
![]() |
N. Toda, K. Ayajiki, and T. Okamura Cerebral Blood Flow Regulation by Nitric Oxide: Recent Advances Pharmacol. Rev., March 1, 2009; 61(1): 62 - 97. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Casey, A. M. Badejo Jr., J. S. Dhaliwal, S. N. Murthy, A. L. Hyman, B. D. Nossaman, and P. J. Kadowitz Pulmonary vasodilator responses to sodium nitrite are mediated by an allopurinol-sensitive mechanism in the rat Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H524 - H533. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Xing, H. Chen, M. Zhang, D. Zhao, R. Jiang, X. Liu, and S. Zhang Ischemic Postconditioning Inhibits Apoptosis After Focal Cerebral Ischemia/Reperfusion Injury in the Rat Stroke, August 1, 2008; 39(8): 2362 - 2369. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Frerart, P. Sonveaux, G. Rath, A. Smoos, A. Meqor, N. Charlier, B. F. Jordan, J. Saliez, A. Noel, C. Dessy, et al. The Acidic Tumor Microenvironment Promotes the Reconversion of Nitrite into Nitric Oxide: Towards a New and Safe Radiosensitizing Strategy Clin. Cancer Res., May 1, 2008; 14(9): 2768 - 2774. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bertuglia Intermittent hypoxia modulates nitric oxide-dependent vasodilation and capillary perfusion during ischemia-reperfusion-induced damage Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1914 - H1922. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Maher, A. B. Milsom, P. Gunaruwan, K. Abozguia, I. Ahmed, R. A. Weaver, P. Thomas, H. Ashrafian, G. V.R. Born, P. E. James, et al. Hypoxic Modulation of Exogenous Nitrite-Induced Vasodilation in Humans Circulation, February 5, 2008; 117(5): 670 - 677. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dejam, C. J. Hunter, C. Tremonti, R. M. Pluta, Y. Y. Hon, G. Grimes, K. Partovi, M. M. Pelletier, E. H. Oldfield, R. O. Cannon III, et al. Nitrite Infusion in Humans and Nonhuman Primates: Endocrine Effects, Pharmacokinetics, and Tolerance Formation Circulation, October 16, 2007; 116(16): 1821 - 1831. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Isbell, M. T. Gladwin, and R. P. Patel Hemoglobin oxygen fractional saturation regulates nitrite-dependent vasodilation of aortic ring bioassays Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2565 - H2572. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Shiva, M. N. Sack, J. J. Greer, M. Duranski, L. A. Ringwood, L. Burwell, X. Wang, P. H. MacArthur, A. Shoja, N. Raghavachari, et al. Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer J. Exp. Med., September 3, 2007; 204(9): 2089 - 2102. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-H. Jung, K. Chu, S.-T. Lee, S.-J. Kim, E.-C. Song, E.-H. Kim, D.-K. Park, D.-I. Sinn, J.-M. Kim, M. Kim, et al. Blockade of AT1 Receptor Reduces Apoptosis, Inflammation, and Oxidative Stress in Normotensive Rats with Intracerebral Hemorrhage J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1051 - 1058. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dezfulian, N. Raat, S. Shiva, and M. T. Gladwin Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics Cardiovasc Res, July 15, 2007; 75(2): 327 - 338. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |